Literature DB >> 26496462

Pathogenic T helper type 17 cells contribute to type 1 diabetes independently of interleukin-22.

S M Bellemore1, E Nikoopour1, O Krougly1, E Lee-Chan1, L A Fouser2, B Singh1.   

Abstract

We have shown that pathogenic T helper type 17 (Th17) cells differentiated from naive CD4(+) T cells of BDC2·5 T cell receptor transgenic non-obese diabetic (NOD) mice by interleukin (IL)-23 plus IL-6 produce IL-17, IL-22 and induce type 1 diabetes (T1D). Neutralizing interferon (IFN)-γ during the polarization process leads to a significant increase in IL-22 production by these Th17 cells. We also isolated IL-22-producing Th17 cells from the pancreas of wild-type diabetic NOD mice. IL-27 also blocked IL-22 production from diabetogenic Th17 cells. To determine the functional role of IL-22 produced by pathogenic Th17 cells in T1D we neutralized IL-22 in vivo by using anti-IL-22 monoclonal antibody. We found that blocking IL-22 did not alter significantly adoptive transfer of disease by pathogenic Th17 cells. Therefore, IL-22 is not required for T1D pathogenesis. The IL-22Rα receptor for IL-22 however, increased in the pancreas of NOD mice during disease progression and based upon our and other studies we suggest that IL-22 may have a regenerative and protective role in the pancreatic islets.
© 2015 British Society for Immunology.

Entities:  

Keywords:  IL-22; Th17 cells; autoimmunity; type 1 diabetes

Mesh:

Substances:

Year:  2015        PMID: 26496462      PMCID: PMC4750601          DOI: 10.1111/cei.12735

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress.

Authors:  Sumaira Z Hasnain; Danielle J Borg; Brooke E Harcourt; Hui Tong; Yonghua H Sheng; Choa Ping Ng; Indrajit Das; Ran Wang; Alice C-H Chen; Thomas Loudovaris; Thomas W Kay; Helen E Thomas; Jonathan P Whitehead; Josephine M Forbes; Johannes B Prins; Michael A McGuckin
Journal:  Nat Med       Date:  2014-11-02       Impact factor: 53.440

2.  Decreased apoptosis in polyamine depleted IEC-6 cells depends on Akt-mediated NF-kappaB activation but not GSK3beta activity.

Authors:  S Bhattacharya; R M Ray; L R Johnson
Journal:  Apoptosis       Date:  2005-08       Impact factor: 4.677

Review 3.  Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22.

Authors:  Gregory F Sonnenberg; Lynette A Fouser; David Artis
Journal:  Nat Immunol       Date:  2011-05       Impact factor: 25.606

4.  Chromogranin A is an autoantigen in type 1 diabetes.

Authors:  Brian D Stadinski; Thomas Delong; Nichole Reisdorph; Richard Reisdorph; Roger L Powell; Michael Armstrong; Jon D Piganelli; Gene Barbour; Brenda Bradley; Frances Crawford; Philippa Marrack; Sushil K Mahata; John W Kappler; Kathryn Haskins
Journal:  Nat Immunol       Date:  2010-02-07       Impact factor: 25.606

5.  IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation.

Authors:  Hak-Ling Ma; Spencer Liang; Jing Li; Lee Napierata; Tom Brown; Stephen Benoit; Mayra Senices; Davinder Gill; Kyriaki Dunussi-Joannopoulos; Mary Collins; Cheryl Nickerson-Nutter; Lynette A Fouser; Deborah A Young
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

Review 6.  IL-27-induced modulation of autoimmunity and its therapeutic potential.

Authors:  Rakeshchandra R Meka; Shivaprasad H Venkatesha; Steven Dudics; Bodhraj Acharya; Kamal D Moudgil
Journal:  Autoimmun Rev       Date:  2015-08-05       Impact factor: 9.754

7.  IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells.

Authors:  Caroline Diveu; Mandy J McGeachy; Katia Boniface; Jason S Stumhofer; Manjiri Sathe; Barbara Joyce-Shaikh; Yi Chen; Cristina M Tato; Terrill K McClanahan; René de Waal Malefyt; Christopher A Hunter; Daniel J Cua; Robert A Kastelein
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

Review 8.  IL-22, not simply a Th17 cytokine.

Authors:  Sascha Rutz; Céline Eidenschenk; Wenjun Ouyang
Journal:  Immunol Rev       Date:  2013-03       Impact factor: 12.988

9.  Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease.

Authors:  Sunao Sugita; Yuko Kawazoe; Ayano Imai; Yukiko Yamada; Shintaro Horie; Manabu Mochizuki
Journal:  Arthritis Res Ther       Date:  2012-05-01       Impact factor: 5.156

10.  The involvement of interleukin-22 in the expression of pancreatic beta cell regenerative Reg genes.

Authors:  Thomas Hill; Olga Krougly; Enayat Nikoopour; Stacey Bellemore; Edwin Lee-Chan; Lynette A Fouser; David J Hill; Bhagirath Singh
Journal:  Cell Regen (Lond)       Date:  2013-04-04
View more
  15 in total

Review 1.  IL-17 and limits of success.

Authors:  Zahra Omidian; Rizwan Ahmed; Adebola Giwa; Thomas Donner; Abdel Rahim A Hamad
Journal:  Cell Immunol       Date:  2018-09-17       Impact factor: 4.868

2.  Is There a Role for Bioactive Lipids in the Pathobiology of Diabetes Mellitus?

Authors:  Undurti N Das
Journal:  Front Endocrinol (Lausanne)       Date:  2017-08-02       Impact factor: 5.555

3.  In vivo activation of invariant natural killer T cells induces systemic and local alterations in T-cell subsets prior to preterm birth.

Authors:  N Gomez-Lopez; R Romero; M Arenas-Hernandez; G Schwenkel; D St Louis; S S Hassan; T N Mial
Journal:  Clin Exp Immunol       Date:  2017-05-10       Impact factor: 4.330

4.  Adenoviral gene transfer of a single-chain IL-23 induces psoriatic arthritis-like symptoms in NOD mice.

Authors:  Rafael R Flores; Lana Carbo; Eun Kim; Montina Van Meter; Consuelo M Lopez De Padilla; Jing Zhao; Debora Colangelo; Matthew J Yousefzadeh; Luise A Angelini; Lei Zhang; Enrico Pola; Nam Vo; Christopher H Evans; Andrea Gambotto; Laura J Niedernhofer; Paul D Robbins
Journal:  FASEB J       Date:  2019-06-06       Impact factor: 5.834

5.  DPP-4 Inhibition Leads to Decreased Pancreatic Inflammatory Profile and Increased Frequency of Regulatory T Cells in Experimental Type 1 Diabetes.

Authors:  Mariana Rodrigues Davanso; Carolina Caliari-Oliveira; Carlos Eduardo Barra Couri; Dimas Tadeu Covas; Angela Merice de Oliveira Leal; Júlio César Voltarelli; Kelen Cristina Ribeiro Malmegrim; Juliana Navarro Ueda Yaochite
Journal:  Inflammation       Date:  2019-04       Impact factor: 4.092

6.  An epigenome-wide study of body mass index and DNA methylation in blood using participants from the Sister Study cohort.

Authors:  L E Wilson; S Harlid; Z Xu; D P Sandler; J A Taylor
Journal:  Int J Obes (Lond)       Date:  2016-10-24       Impact factor: 5.095

7.  Proteins of TNF-α and IL6 Pathways Are Elevated in Serum of Type-1 Diabetes Patients with Microalbuminuria.

Authors:  Sharad Purohit; Ashok Sharma; Wenbo Zhi; Shan Bai; Diane Hopkins; Leigh Steed; Bruce Bode; Stephen W Anderson; John Chip Reed; R Dennis Steed; Jin-Xiong She
Journal:  Front Immunol       Date:  2018-01-31       Impact factor: 7.561

8.  RIG-I antiviral signaling drives interleukin-23 production and psoriasis-like skin disease.

Authors:  Huiyuan Zhu; Fangzhou Lou; Qianqian Yin; Yuanyuan Gao; Yang Sun; Jing Bai; Zhenyao Xu; Zhaoyuan Liu; Wei Cai; Fang Ke; Lingyun Zhang; Hong Zhou; Hong Wang; Gang Wang; Xiang Chen; Hongxin Zhang; Zhugang Wang; Florent Ginhoux; Chuanjian Lu; Bing Su; Honglin Wang
Journal:  EMBO Mol Med       Date:  2017-05       Impact factor: 12.137

9.  CCL24 Protects Renal Function by Controlling Inflammation in Podocytes.

Authors:  Youdi Wang; Xue Wu; Mengya Geng; Jiamin Ding; Kangjia Lv; Hui Du; Jiahui Ding; Wenjun Pei; Xin Hu; Jing Gu; Lizhuo Wang; Yao Zhang; Jialin Gao
Journal:  Dis Markers       Date:  2021-06-16       Impact factor: 3.434

10.  Seroreactivity against Specific L5P Antigen from Mycobacterium avium subsp. paratuberculosis in Children at Risk for T1D.

Authors:  Magdalena Niegowska; Novella Rapini; Frank Biet; Simona Piccinini; Sylvie Bay; Roberta Lidano; Maria Luisa Manca Bitti; Leonardo A Sechi
Journal:  PLoS One       Date:  2016-06-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.